These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25584889)

  • 21. New applications of gemcitabine and future directions in the management of pancreatic cancer.
    Abbruzzese JL
    Cancer; 2002 Aug; 95(4 Suppl):941-5. PubMed ID: 12209675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan.
    Iede K; Yamada T; Koh M; Ueda M; Tsuda Y; Nakashima S; Ohta K; Tanida T; Matsuyama J; Ikenaga M; Tominaga S
    Pancreas; 2022 Jan; 51(1):e4-e6. PubMed ID: 35195606
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pancreatic cancer--diagnostics and therapy].
    Schramm H
    Zentralbl Chir; 2003 May; 128(5):367. PubMed ID: 12813632
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
    Zhang Z; Ji S; Hu Q; Zhuo Q; Liu W; Xu W; Liu W; Liu M; Ye Z; Fan G; Xu X; Yu X; Qin Y
    Clin Transl Med; 2021 Aug; 11(8):e398. PubMed ID: 34459132
    [No Abstract]   [Full Text] [Related]  

  • 27. It's what's inside that counts.
    Shewach DS; Lawrence TS
    J Clin Oncol; 2003 Sep; 21(18):3383-4. PubMed ID: 12885832
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
    Hasnis E; Alishekevitz D; Gingis-Veltski S; Bril R; Fremder E; Voloshin T; Raviv Z; Karban A; Shaked Y
    Neoplasia; 2014 Jun; 16(6):501-10. PubMed ID: 24957319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound and microbubble assisted drug delivery - A clinical pharmacological perspective.
    Bjånes TK; Riedel B; Schjøtt J
    Pharmacol Res; 2021 Mar; 165():105475. PubMed ID: 33524538
    [No Abstract]   [Full Text] [Related]  

  • 30. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
    Guais A; Baronzio G; Sanders E; Campion F; Mainini C; Fiorentini G; Montagnani F; Behzadi M; Schwartz L; Abolhassani M
    Invest New Drugs; 2012 Feb; 30(1):200-11. PubMed ID: 20931262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
    Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
    Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
    Sugisawa N; Miyake K; Higuchi T; Oshiro H; Zhang Z; Park JH; Kawaguchi K; Chawla SP; Bouvet M; Singh SR; Unno M; Hoffman RM
    Anticancer Res; 2019 Oct; 39(10):5339-5344. PubMed ID: 31570427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transport properties of pancreatic cancer describe gemcitabine delivery and response.
    Koay EJ; Truty MJ; Cristini V; Thomas RM; Chen R; Chatterjee D; Kang Y; Bhosale PR; Tamm EP; Crane CH; Javle M; Katz MH; Gottumukkala VN; Rozner MA; Shen H; Lee JE; Wang H; Chen Y; Plunkett W; Abbruzzese JL; Wolff RA; Varadhachary GR; Ferrari M; Fleming JB
    J Clin Invest; 2014 Apr; 124(4):1525-36. PubMed ID: 24614108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
    Sakamoto H; Kitano M; Suetomi Y; Takeyama Y; Ohyanagi H; Nakai T; Yasuda C; Kudo M
    J Gastroenterol; 2006 Jan; 41(1):70-6. PubMed ID: 16501860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of advanced pancreatic cancer treated with gemcitabine hydrochloride].
    Taniguchi F; Matsuda T; Tsuda T; Aikawa I
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1147-9. PubMed ID: 12938271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
    Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
    Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
    Zhang GN; Liang Y; Zhou LJ; Chen SP; Chen G; Zhang TP; Kang T; Zhao YP
    Cancer Lett; 2011 Dec; 313(2):137-44. PubMed ID: 22030254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined gemcitabine and alpha-interferon therapy for pancreatic cancer: report of a case.
    Sawai H; Okada Y; Tanaka M; Funahashi H; Yamamoto M; Takeyama H; Manabe T
    Dig Dis Sci; 2006 Jul; 51(7):1285-9. PubMed ID: 16944027
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
    Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
    Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.
    Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF
    J Pharmacol Exp Ther; 2017 Mar; 360(3):445-456. PubMed ID: 28028124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.